{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(2)"],"submitter":["Pluda S"],"pubmed_abstract":["<h4>Objective</h4> Osteoarthritis (OA) is a painful degenerative disease of the whole joint structure, including articular cartilage, synovial fluid, and subchondral bone. Hyaluronic acid (HA), an anionic non-sulfated glycosaminoglycan, is commonly used for intra-articular (IA) treatment in OA, while bisphosphonates (BPs) are anti-resorptive drugs that act on the bone. Here, a novel conjugate with a covalent and hydrolysable linker between HA and alendronate (ALD) was designed as an attractive therapeutic strategy for IA drug delivery. <h4>Design</h4> The HA-ALD derivative was synthesized and tested in comparison with a simple mixture of HA and ALD for in vitro ALD release, rheological properties, cytotoxicity towards osteoblasts and chondrocytes and in an in vitro efficacy assay of OA inf"],"journal":["Osteoarthritis and cartilage open"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9718194"],"repository":["biostudies-literature"],"pubmed_title":["Hyaluronic acid-alendronate conjugate: A macromolecular drug delivery system for intra-articular treatment of osteoarthritis"],"pmcid":["PMC9718194"],"pubmed_authors":["Fassina L","Soato M","Galesso D","Pluda S","Barbera C","di Lucia A","Guarise C","Pavan M","Gatti F","Beninatto R"],"additional_accession":[]},"is_claimable":false,"name":"Hyaluronic acid-alendronate conjugate: A macromolecular drug delivery system for intra-articular treatment of osteoarthritis","description":"<h4>Objective</h4> Osteoarthritis (OA) is a painful degenerative disease of the whole joint structure, including articular cartilage, synovial fluid, and subchondral bone. Hyaluronic acid (HA), an anionic non-sulfated glycosaminoglycan, is commonly used for intra-articular (IA) treatment in OA, while bisphosphonates (BPs) are anti-resorptive drugs that act on the bone. Here, a novel conjugate with a covalent and hydrolysable linker between HA and alendronate (ALD) was designed as an attractive therapeutic strategy for IA drug delivery. <h4>Design</h4> The HA-ALD derivative was synthesized and tested in comparison with a simple mixture of HA and ALD for in vitro ALD release, rheological properties, cytotoxicity towards osteoblasts and chondrocytes and in an in vitro efficacy assay of OA inf","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-26T20:45:54.922Z","creation":"2025-04-06T16:31:49.772Z"},"accession":"S-EPMC9718194","cross_references":{}}